Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia

被引：0
|
作者：
De Botton, Stephane
Jonas, Brian Andrew
Ferrell, P. Brent
Chao, Mwe Mwe
Mims, Alice S.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Rigel Pharmaceut Inc, South San Francisco, CA USA
[5] Ohio State Univ, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6527
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
    Usuki, Kensuke
    Handa, Hiroshi
    Choi, Ilseung
    Yamauchi, Takahiro
    Iida, Hiroatsu
    Hata, Tomoko
    Ohwada, Shoichi
    Okudaira, Noriko
    Nakamura, Kota
    Sakajiri, Sakura
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 654 - 664
  • [32] Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia
    Wang, Liang
    Li, Chun
    Xu, Fang
    Cao, Fang
    Zhang, Bo
    Wang, Jing
    Wang, Shen
    Chen, Li
    Li, Na
    Liao, Chenglin
    Liu, Hongjun
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 15 (06)
  • [33] Efficacy and safety of the combination of decitabine and CHAG priming regimen in the relapsed or refractory acute myeloid leukemia
    Wu, Yan
    Liang, Jinping
    Mi, Ruihua
    Wang, Lin
    Chen, Lin
    Wei, Xudong
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [34] Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia
    Buettner, Bozena
    Knoth, Holger
    Kramer, Michael
    Oertel, Reinhard
    Seeling, Andreas
    Sockel, Katja
    von Bonin, Malte
    Stoelzel, Friedrich
    Alakel, Nael
    Platzbecker, Uwe
    Roellig, Christoph
    Ehninger, Gerhard
    Bornhaeuser, Martin
    Schetelig, Johannes
    Middeke, Jan Moritz
    LEUKEMIA & LYMPHOMA, 2017, 58 (12) : 2865 - 2874
  • [35] Efficacy and safety of fludarabine combined with cytarabine in the treatment of patients with relapsed and refractory acute lymphoblastic leukemia (ALL).
    Jiang, B
    Wang, W
    Bao, L
    Huang, XJ
    Lu, J
    Wang, DB
    Lu, DP
    BLOOD, 2005, 106 (11) : 227B - 227B
  • [36] The search for optimal treatment in relapsed and refractory acute myeloid leukemia
    Robak, T
    Wrzesien-Kus, A
    LEUKEMIA & LYMPHOMA, 2002, 43 (02) : 281 - 291
  • [37] TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA IN ADULTS
    LAZZARINO, M
    MORRA, E
    ALESSANDRINO, EP
    MERANTE, S
    BERNASCONI, P
    BONFICHI, M
    CALDERA, D
    BERNASCONI, C
    BONE MARROW TRANSPLANTATION, 1989, 4 : 121 - 123
  • [38] IDARUBICIN IN THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID-LEUKEMIA
    HAROUSSEAU, JL
    HURTELOUP, P
    REIFFERS, J
    RIGALHUGUET, F
    HAYAT, M
    DUFOUR, P
    LEPRISE, PY
    MONCONDUIT, M
    JAUBERT, J
    CARCASSONNE, Y
    CANCER TREATMENT REPORTS, 1987, 71 (10): : 991 - 992
  • [39] Repurposing disulfiram for treatment of relapsed/refractory acute myeloid leukemia
    Aleem, Eiman A.
    Azorsa, David O.
    Bista, Ranjan
    Pepper, Oliver B.
    Lee, David W.
    Wai, Daniel H.
    Arceci, Robert J.
    CANCER RESEARCH, 2014, 74 (19)
  • [40] Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
    Ramos, Nestor R.
    Mo, Clifton C.
    Karp, Judith E.
    Hourigan, Christopher S.
    JOURNAL OF CLINICAL MEDICINE, 2015, 4 (04) : 665 - 695
12345